New combo therapy aims to tackle breast cancer brain metastases

NCT ID NCT04923542

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether combining a targeted drug (abemaciclib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a common type of breast cancer (HR+/HER2-). About 31 participants will receive both treatments along with hormone therapy. The main goal is to see how long the brain tumors stay under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abemaciclib (Verzenio) and stereotactic radiosurgery
What this could lead to: If successful, this combination could offer a new way to control brain metastases in HR+/HER2- breast cancer, potentially delaying progression and improving outcomes.
What could go wrong: This is an early-phase, single-arm study with only 31 participants, so results may not apply broadly. Side effects from the drug or radiation could be significant, and the treatment may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer hormone receptor-positive breast cancer metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES HR+ METASTATIC BREAST CANCER

Contacts and locations

Locations

Moffitt Cancer Center
ACTIVE_NOT_RECRUITING

Tampa, Florida, 33612, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.